At Johnson & Johnson, we take on the world’s most pervasive diseases that disrupt the lives of millions – including our loved ones, our colleagues, and ourselves. As part of this long-standing commitment, we seek highly-differentiated medicines that prevent and treat cardiovascular diseases – the leading cause of death worldwide, and a soaring strain on global health systems.
We relentlessly pursue mature innovation, both inside and beyond our own walls, that holds the highest potential for preventing, reversing, treating, and even curing the most prevalent forms of heart disease. In doing so, we expedite hope to people in need and can make a meaningful difference in their lives every day.
Our Phase 3 Librexia program, the most comprehensive FXIa inhibitor clinical development program today, is evaluating patients in three studies – event reduction in acute coronary syndromes, stroke prevention in atrial fibrillation, and stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack.
Through our ongoing efforts, we aim to address unmet needs for the millions of patients impacted by stroke and cardiovascular diseases worldwide. Watch our videos below to learn more.
